dndn and onc.res.intl.ltd., page-15

once again, you are beside the point as you keep referring to applications not targeted by ACL yet.

As explained in numerous postings, ACL is worth $2.50 on the back of gen Fonda (exclusively replacing a continuously growing Arixtra), + $xx for oral fonda + $$ for HA-irinotecan and this is where we are focused on.

You then mention other stuff not explored by ACL, and therefore not relevant. That said, I am sure other threads (than ACL) would welcome your insights... why don't you go and look for them ?? and let us deal between ourselves with what you may consider as minor stuff.